Journal of Clinical Oncology, Vol 23, No 26 (September 10), 2005: pp. 6409-6414
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.55.017
Current Treatment Approaches for Mantle-Cell Lymphoma
Thomas E. Witzig
From the Mayo Clinic College of Medicine and Mayo Foundation Rochester, MN
Address reprint requests to Thomas E. Witzig, MD, Mayo Clinic, Stabile 628, 200 First St SW, Rochester, MN 55905; e-mail: Witzig{at}mayo.edu.
Mantle-cell lymphoma (MCL) is now recognized as a distinct clinicopathologic subtype of B-cell non-Hodgkin's lymphoma. Patients with MCL are typically older adults with a male predominance and usually present with stage IV disease. The cells are characterized as CD20+ CD5+ CD23– with a t(11;14)(q13;q32) and cyclin D1 overexpression on immunohistochemistry. Response to chemotherapy usually results in a tumor response but unmaintained remissions are short and the median survival is 3 to 4 years. The treatment approach to newly diagnosed patients with MCL depends on the patient's eligibility for stem cell transplantation (SCT). Those who are eligible are usually treated with either rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by SCT or rituximab-HyperCVAD (cyclophosphamide, vincristine, doxorubicin, decadron, cytarabine, and methotrexate) followed by observation. The purine nucleoside analogues also have activity as single agents and with rituximab. Unfortunately none of these approaches can definitively cure patients with MCL, and new agents are needed. Recent studies in patients with relapsed MCL have shown substantial antitumor activity of single-agent bortezomib, single-agent temsirolimus, and the combination of thalidomide and rituximab. Studies integrating these novel agents earlier in the disease course or in combination with each other will hopefully produce more durable responses with less toxicity.
Supported in part by Grants No. CA97274 and CA25224 from the National Institutes of Health and the National Cancer Institute.
Author's disclosures of potential conflicts of interest are found at the end of this article.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Wang, Y. Oki, B. Pro, J. E. Romaguera, M. A. Rodriguez, F. Samaniego, P. McLaughlin, F. Hagemeister, S. Neelapu, A. Copeland, et al.
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma
J. Clin. Oncol.,
November 1, 2009;
27(31):
5213 - 5218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Psyrri, S. Papageorgiou, E. Liakata, A. Scorilas, D. Rontogianni, C. K. Kontos, P. Argyriou, D. Pectasides, N. Harhalakis, V. Pappa, et al.
Phosphatidylinositol 3'-Kinase Catalytic Subunit {alpha} Gene Amplification Contributes to the Pathogenesis of Mantle Cell Lymphoma
Clin. Cancer Res.,
September 15, 2009;
15(18):
5724 - 5732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Rasmussen, L D Sjo, J U Prause, E Ralfkiaer, and S Heegaard
Mantle cell lymphoma in the orbital and adnexal region
Br J Ophthalmol,
August 1, 2009;
93(8):
1047 - 1051.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Boyd, R. Jukes-Jones, R. Walewska, D. Brown, M. J. S. Dyer, and K. Cain
Protein Profiling of Plasma Membranes Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma
Mol. Cell. Proteomics,
July 1, 2009;
8(7):
1501 - 1515.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Delmonte, M. Ghielmini, and C. Sessa
Beyond Monoclonal Antibodies: New Therapeutic Agents in Non-Hodgkin's Lymphomas
Oncologist,
May 1, 2009;
14(5):
511 - 525.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Goy, S. H. Bernstein, B. S. Kahl, B. Djulbegovic, M. J. Robertson, S. de Vos, E. Epner, A. Krishnan, J. P. Leonard, S. Lonial, et al.
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
Ann. Onc.,
March 1, 2009;
20(3):
520 - 525.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Roue, M. Lopez-Guerra, P. Milpied, P. Perez-Galan, N. Villamor, E. Montserrat, E. Campo, and D. Colomer
Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling
Clin. Cancer Res.,
November 1, 2008;
14(21):
6907 - 6915.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hartmann, V. Fernandez, V. Moreno, J. Valls, L. Hernandez, F. Bosch, P. Abrisqueta, W. Klapper, M. Dreyling, E. Hoster, et al.
Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue
J. Clin. Oncol.,
October 20, 2008;
26(30):
4966 - 4972.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. H. Wiernik, I. S. Lossos, J. M. Tuscano, G. Justice, J. M. Vose, C. E. Cole, W. Lam, K. McBride, K. Wride, D. Pietronigro, et al.
Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
October 20, 2008;
26(30):
4952 - 4957.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Chen, L. T. Bemis, C. M. Amato, H. Myint, H. Tran, D. K. Birks, S. G. Eckhardt, and W. A. Robinson
Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma
Blood,
August 1, 2008;
112(3):
822 - 829.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sander, L. Bullinger, E. Leupolt, A. Benner, D. Kienle, T. Katzenberger, J. Kalla, G. Ott, H. K. Muller-Hermelink, T. F.E. Barth, et al.
Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations
Haematologica,
May 1, 2008;
93(5):
680 - 687.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Michopoulos, K. Petraki, C. Matsouka, E. Kastritis, H. Chrysanthopoulou, and M. A. Dimopoulos
Mantle-Cell Lymphoma (Multiple Lymphomatous Polyposis) of the Entire GI Tract
J. Clin. Oncol.,
March 20, 2008;
26(9):
1555 - 1557.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Morschhauser, J. F. Seymour, H. C. Kluin-Nelemans, A. Grigg, M. Wolf, M. Pfreundschuh, H. Tilly, J. Raemaekers, M. B. van 't Veer, N. Milpied, et al.
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma
Ann. Onc.,
February 1, 2008;
19(2):
247 - 253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ferrer, F. Bosch, N. Villamor, M. Rozman, F. Graus, G. Gutierrez, S. Mercadal, E. Campo, C. Rozman, A. Lopez-Guillermo, et al.
Central nervous system involvement in mantle cell lymphoma
Ann. Onc.,
January 1, 2008;
19(1):
135 - 141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Kawamata, J. Chen, and H. P. Koeffler
Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells
Blood,
October 1, 2007;
110(7):
2667 - 2673.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Wang, L. Zhang, X. Han, J. Yang, J. Qian, S. Hong, F. Samaniego, J. Romaguera, and Q. Yi
Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways
Blood,
June 15, 2007;
109(12):
5455 - 5462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F Morschhauser, S Depil, E Jourdan, M Wetterwald, R Bouabdallah, G Marit, P Solal-Celigny, C Sebban, B Coiffier, N Chouaki, et al.
Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma
Ann. Onc.,
February 1, 2007;
18(2):
370 - 375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. I. Fisher, S. H. Bernstein, B. S. Kahl, B. Djulbegovic, M. J. Robertson, S. de Vos, E. Epner, A. Krishnan, J. P. Leonard, S. Lonial, et al.
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
J. Clin. Oncol.,
October 20, 2006;
24(30):
4867 - 4874.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
